Short-limb skeletal dysplasia with severe combined immunodeficiency

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

2 events
Oct 2018

Revcovi: FDA approved

Treatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID).

FDAcompleted
Mar 1990

Adagen: FDA approved

For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

Adagen

Sigma-tau Pharmaceuticals, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Adagen

(Pegademase bovine)Orphan drug

Sigma-tau Pharmaceuticals, Inc.

Approved Mar 1990

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Short-limb skeletal dysplasia with severe combined immunodeficiency.
Search all trials →
Search clinical trials for Short-limb skeletal dysplasia with severe combined immunodeficiency

Recent News & Research

No recent news articles indexed yet for Short-limb skeletal dysplasia with severe combined immunodeficiency.
Search PubMed for Short-limb skeletal dysplasia with severe combined immunodeficiency

Browse all Short-limb skeletal dysplasia with severe combined immunodeficiency news →

Specialist Network

No specialists currently listed for Short-limb skeletal dysplasia with severe combined immunodeficiency.

View all Short-limb skeletal dysplasia with severe combined immunodeficiency specialists →

Quick Actions